ArticleEuropean journal of medical research2026
Comparing the diagnostic performance of metabolic indices in metabolic dysfunction-associated fatty liver disease patients: a retrospective cross-sectional study.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as the leading cause of liver dysfunction and poses a significant risk for progression to cirrhosis. In this study, we aimed to compare the ability of various metabolic indices and identify those most effective for the prediction of MAFLD.
methodsThis cross-sectional study included 1471 patients (69.6% MAFLD) between 2011 and 2024. Specific metabolic indices were calculated. The associations between indices and MAFLD were analyzed via logistic regression analysis and restricted cubic splines. The prediction ability of the indices was evaluated via receiver operating characteristic (ROC) analysis in different subgroups.
resultsTriglyceride glucose (TyG) index, homeostatic model assessment for insulin resistance (HOMA-IR), and estimated glucose disposal rate (eGDR) had the strongest associations with MAFLD (final adjusted ORs for TyG = 3.60, HOMA-IR = 3.35, eGDR = 2.97 per unit change). According to the ROC curve analysis, TyG index and hepatic steatosis index (HSI) had the highest area under the curve (AUC) for the prediction of MAFLD in females (AUC = 0.832) and males (AUC = 0.848), respectively. TyG also performed the best in lean/normal-weight and overweight/obesity individuals, with AUCs of 0.890 and 0.787, respectively. TyG in those ≥ 65 years old (AUC = 0.844) and eGDR in those < 65 years old (AUC = 0.843) had the highest prediction performance for MAFLD.
conclusionInsulin resistance markers, including TyG, HOMA-IR, and eGDR, had the strongest associations with MAFLD. For predicting MAFLD, TyG had the highest performance across all subgroups, except for males and those < 65 years, where HSI and eGDR performed better, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.